Probiotics in irritable bowel syndrome: Should we give full name?;Probióticos en el síndrome de intestino irritable: ¿debemos darles nombre y apellidos?

Revista Espanola de Enfermedades Digestivas

Volumn 105, Issue 1, 2013, Pages 1-2

  Álvarez Sánchez, Ángel ^a   Rey, Enrique ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; PROBIOTIC AGENT;

DRUG CLASSIFICATION; DRUG EFFICACY; EDITORIAL; HUMAN; IRRITABLE COLON; META ANALYSIS (TOPIC); NOMENCLATURE; PATIENT CARE; BIFIDOBACTERIUM; DIET THERAPY; LACTOBACILLUS;

BIFIDOBACTERIUM; HUMANS; IRRITABLE BOWEL SYNDROME; LACTOBACILLUS; PROBIOTICS;

EID: 84878572409     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082013000100001     Document Type: Editorial

References (13)

1. Rey E, Talley NJ. Irritable bowel syndrome: novel views on the epidemiology and potential risk factors. Dig Liver Dis 2009;41:772-80.
2. Almansa C, Diaz-Rubio M, Rey E. The burden and management of patients with IBS: Results from a survey in spanish gastroenterologists. Rev Esp Enferm Dig 2011;103:570-5.
3. Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7:1279-86.
4. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32.
5. Yu D, Cheeseman F, Vanner S. Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011;60:334-40.
6. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004;292:852-8.
7. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187-9.
8. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:512-5.
9. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007;19:166-72.
10. Bixquert Jimenez M. Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? Rev Esp Enferm Dig 2009;10:553-64.
11. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14:2650-61.
12. Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15.
13. Ortiz-Lucas M, Tobias A, Saz P, Sebastián JJ. Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis. Rev Esp Enferm Dig 2013;105:19-36.